Skip to content

MiNK Therapeutics, Inc.: 10-Q filed 2025-08-14

What MiNK Therapeutics, Inc. reported in its quarterly report filed 2025-08-14 (fiscal Q2 2025): 30 published measures, 90 facts as tagged in accession 0000950170-25-108894.

This filing

Form
10-Q (quarterly report)
Filed
2025-08-14
Fiscal period
fiscal Q2 2025
Accession
0000950170-25-108894 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All MiNK Therapeutics, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-06-302,484,417USD
At 2024-12-315,720,813USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-06-30-25,189,315USD
At 2025-03-31-21,791,779USD
At 2024-12-31-19,585,882USD
At 2024-06-30-16,576,143USD
At 2024-03-31-20,299,207USD
At 2023-12-31-18,055,449USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2025-06-301,681,915USD
At 2024-12-314,577,040USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-4,237,751USD91
2025-01-01 to 2025-06-30-7,004,448USD181
2025-01-01 to 2025-03-31-2,766,697USD90
2024-04-01 to 2024-06-30-2,701,806USD91
2024-01-01 to 2024-06-30-6,515,101USD182
2024-01-01 to 2024-03-31-3,813,295USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-01-01 to 2025-06-30-2,910,094USD181
2024-01-01 to 2024-06-30-4,832,887USD182

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2025-01-01 to 2025-06-301,116USD181
2024-01-01 to 2024-06-3010,813,184USD182

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-06-30-151,186,183USD
At 2024-12-31-144,181,735USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-04-01 to 2025-06-303,981,992shares91
2025-01-01 to 2025-06-303,973,534shares181
2024-04-01 to 2024-06-303,714,202shares91
2024-01-01 to 2024-06-303,589,247shares182

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-04-01 to 2025-06-303,981,992shares91
2025-01-01 to 2025-06-303,973,534shares181
2024-04-01 to 2024-06-303,714,202shares91
2024-01-01 to 2024-06-303,589,247shares182

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-1.06USD/shares91
2025-01-01 to 2025-06-30-1.76USD/shares181
2024-04-01 to 2024-06-30-0.73USD/shares91
2024-01-01 to 2024-06-30-1.82USD/shares182

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-1.06USD/shares91
2025-01-01 to 2025-06-30-1.76USD/shares181
2024-04-01 to 2024-06-30-0.73USD/shares91
2024-01-01 to 2024-06-30-1.82USD/shares182

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2025-06-30473,215USD
At 2024-12-31732,929USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2025-01-01 to 2025-06-301,487,641USD181
2024-01-01 to 2024-06-301,028,880USD182

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-4,052,396USD91
2025-01-01 to 2025-06-30-6,753,083USD181
2024-04-01 to 2024-06-30-3,071,081USD91
2024-01-01 to 2024-06-30-6,900,995USD182

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-06-302,011,202USD
At 2024-12-314,987,884USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-27,000USD91
2025-01-01 to 2025-06-30-55,000USD181
2024-04-01 to 2024-06-30-26,000USD91
2024-01-01 to 2024-06-30-36,000USD182

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-06-3013,163,565USD
At 2024-12-316,959,676USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2025-06-303,314,839USD
At 2024-12-312,728,212USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2025-04-01 to 2025-06-301,839,176USD91
2025-01-01 to 2025-06-303,101,077USD181
2024-04-01 to 2024-06-301,839,874USD91
2024-01-01 to 2024-06-304,389,355USD182

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2025-06-301,681,915USD
At 2024-12-314,577,040USD
At 2024-06-309,313,668USD
At 2023-12-313,367,229USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2025-06-30-719,318USD
At 2024-12-31-631,576USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2025-06-30530,582USD
At 2024-12-31524,639USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2025-06-301,861,464USD
At 2024-12-311,873,561USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2025-01-01 to 2025-06-30-7,004,448USD181
2024-01-01 to 2024-06-30-6,515,101USD182

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-4,294,628USD91
2025-01-01 to 2025-06-30-7,092,190USD181
2024-04-01 to 2024-06-30-2,927,401USD91
2024-01-01 to 2024-06-30-6,695,529USD182

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2025-04-01 to 2025-06-301,849,130USD91
2025-01-01 to 2025-06-303,119,994USD181
2024-04-01 to 2024-06-301,061,793USD91
2024-01-01 to 2024-06-302,342,226USD182

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2025-01-01 to 2025-06-3099,528USD181
2024-01-01 to 2024-06-3098,931USD182

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-185,703USD91
2025-01-01 to 2025-06-30-265,230USD181
2024-04-01 to 2024-06-30330,915USD91
2024-01-01 to 2024-06-30330,915USD182

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2025-01-01 to 2025-06-305,695USD181
2024-01-01 to 2024-06-306,414USD182

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2025-01-01 to 2025-06-30577,453USD181
2024-01-01 to 2024-06-30-709,213USD182

Inspect the source

Entity
MiNK Therapeutics, Inc. / CIK 0001840229
Captured
2026-09-21T17:29:59.682Z
SEC response SHA-256
379e7984f39fecf40700776a838a67706b02060bd609a2e40e4f28d70bf01adb

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001840229.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))